Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK3 | O43293 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | LTK | P29376 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CDK7 | P50613 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656542 | 0.77 | CHEK1 (0.31) | DAPK3MAP4K4ABL1NTRK1LCK | |
| SCHEMBL18342618 | 0.75 | HTT (0.32) | DAPK3MAP4K4ABL1NTRK1LCK | |
| SCHEMBL30362436 | 0.75 | MRGPRX1 (0.33) | DAPK3MAP4K4ABL1NTRK1LCK | |
| SCHEMBL8274148 | 0.75 | MRGPRX1 (0.33) | DAPK3MAP4K4ABL1NTRK1LCK | |
| SCHEMBL13920407 | 0.75 | CYP2A6 (0.39) | DAPK3MAP4K4ABL1NTRK1LCK | |
| SCHEMBL31462337 | 0.72 | PKM (0.31) | — | |
| SCHEMBL30493448 | 0.72 | RPS6KB1 (0.38) | — | |
| SCHEMBL28013549 | 0.72 | RPS6KB1 (0.38) | — | |
| SCHEMBL22430452 | 0.71 | DGAT1 (0.30) | — | |
| SCHEMBL25943580 | 0.71 | ELANE (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255893-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | The Johns Hopkins University (US) | 2023-10-11 | — | — | EP | claimed |
| WO-2022119823-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-09 | — | — | WO | claimed |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | THE JOHNS HOPKINS UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2006100095-A1 | SUBSTITUTED CARBOXAMIDES METHOD FOR PRODUCTION AND USE THEREOF AS TNF-ALPHA RELEASE INHIBITORS | CURACYTE DISCOVERY GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | DAPK3 1010/4885MAP4K4 1430/4885ABL1 1860/4885 |
| US-20240002395-A1 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | MRGPRX1, MRGPRX4, MRGPRX2 | DAPK3 1231/4885MAP4K4 744/4885ABL1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.